Sicca Symptoms in Parkinson’s Disease: Association with Other Nonmotor Symptoms and Health-Related Quality of Life
Table 3
Group comparison of subjects with and without sicca symptoms.
Subjects without sicca symptoms
Subjects with sicca symptoms
Sex (no., %)
Female
6
28
0.03
Male
23
36
Age (mean, SD; years)
65.7
9.1
67.5
10.5
0.44
Survey of autonomic symptoms total score (mean, SD)
5.4
4.9
12.8
6.1
<0.001
Hoehn and Yahr (median, IQR)
2.5
1
3
1
0.11
MDS-UPDRS III (mean, SD)
31.1
12.9
31.5
14.3
0.89
NMS-Quest (mean, SD)
6.2
3.1
12.3
4.1
<0.001
Disease duration (mean, SD; months)
94.5
74.5
127.1
82.6
0.09
Levodopa equivalent daily dose (mean, SD, mg)
567
431
874
778
0.11
Health-related QoL (mean, SD)
(i) PDQ-39 mobility
38.1
32.7
56.5
25.6
0.007
(ii) PDQ-39 activities of daily living
28.9
25.3
43.6
26.1
0.015
(iii) PDQ-39 emotional well-being
20.9
22.8
40.4
23.0
<0.001
(iv) PDQ-39 stigmatisation
12.1
18.2
22.0
24.8
0.06
(v) PDQ-39 social support
10.7
16.1
17.7
19.1
0.10
(vi) PDQ-39 cognition
22.0
17.2
39.7
21.3
<0.001
(vii) PDQ-39 communication
21.8
24.6
28.0
20.6
0.22
(viii) PDQ-39 bodily discomfort
23.7
23.5
42.1
25.1
0.002
(ix) PDQ-39 summary index
22.3
16.1
35.9
15.8
0.001
Abbreviations. MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; NMS-Quest, revised nonmotor symptoms questionnaire; PDQ-39, Parkinson’s disease quality of life questionnaire.
